The World Health Organisation (WHO) has warned that patients are increasingly running out of treatment options as antibiotics become less effective against infections, noting that the situation has deteriorated compared with 2019.
The WHO, in a statement on Wednesday, said common bacteria were developing significant resistance to first-line antibiotics and even drugs reserved as a last resort. The warning was issued ahead of World Antimicrobial Resistance Awareness Week (WAAW), observed annually from November 18 to 24 to promote awareness and global action against drug-resistant infections.
The warning was issued jointly with the European Centre for Disease Prevention and Control following an assessment of efforts to reduce infections caused by drug-resistant bacteria, commonly known as superbugs, particularly in healthcare facilities. The report showed that infections caused by Klebsiella pneumoniae, a common hospital-acquired bacterium, increased by an estimated 72 per cent between 2019 and 2025, instead of meeting the target of a five per cent reduction.
Similarly, infections caused by E. coli, which is resistant to commonly used antibiotics known as cephalosporins, rose by more than 16 per cent, despite a target of reducing them by 10 per cent. WHO also found that resistance to key antibiotics in Klebsiella pneumoniae and Acinetobacter was detected in at least half of samples in about one in two European countries.
The head of health security at WHO/Europe, Marc-Alain Widdowson, said antibiotics commonly prescribed by doctors as the first line of treatment were failing against serious hospital infections in many countries. He explained that when these drugs become ineffective, doctors resort to stronger medications known as carbapenems, which are usually reserved for severe infections.
He warned that when carbapenems also fail, treatment options become limited to a small group of last-resort drugs, which are often expensive and unavailable in some countries. According to him, the loss of each line of defence brings patients closer to having no effective treatment options, increasing the likelihood of death among those whose initial antibiotic treatment fails.
WHO further disclosed that 16 of the 51 countries assessed still lacked standardised national strategies and coordination mechanisms to tackle antimicrobial resistance, making efforts to address the problem more difficult.
The agency also noted that hospitals with inadequate blood-sample testing often leave doctors with little information about the bacteria responsible for infections, forcing them to prescribe antibiotics without knowing which medication would be effective.
It warned that this increases the chances of patients receiving ineffective treatment while leaving health authorities with insufficient data to monitor the spread of drug resistance and assess the impact of control measures.
Widdowson stressed that improved testing would help doctors identify effective treatments more quickly while providing countries with better information to tackle the growing threat.
However, WHO reported some progress, noting that the estimated rate of bloodstream infections caused by antibiotic-resistant Acinetobacter had almost halved from the high levels recorded in 2021 during the COVID-19 pandemic.
(NAN)

